NASDAQ Welcomes Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NASDAQ Welcomes Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to The NASDAQ Stock Market

NEW YORK, Oct. 25, 2013 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq: NDAQ ) announced that trading of Aerie Pharmaceuticals, Inc. (Nasdaq: AERI ), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, commenced on The NASDAQ Stock Market on October 25, 2013.

Aerie's lead product candidate, AR-13324, is the first of a new dual-action drug class that was discovered by Aerie scientists. AR-13324 is a once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. Aerie's product candidate PG324 is a fixed combination of dual-action AR-13324 with latanoprost formulated in a single eye drop and is designed to lower intraocular pressure by reducing fluid inflow while also opening both of the eye's fluid drains.

Aerie is located in Bedminster, New Jersey, Research Triangle Park, North Carolina, and Newport Beach, California.

"Aerie truly exemplifies the spirit of innovation through their development of novel therapeutics," said Nelson Griggs, Senior Vice President, NASDAQ OMX Corporate Client Group, "We congratulate Aerie on their initial public offering and look forward to a successful and enduring partnership in the future."

Aerie Pharmaceuticals joins a variety of cutting-edge biotechnology companies that call NASDAQ OMX home. NASDAQ has been the exchange of choice to 97 percent of biotechnology companies that have listed on the U.S. markets year-to-date in 2013.

About NASDAQ OMX Group :

The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily.  Welcome to the NASDAQ OMX Century.  To learn more, visit nasdaqomx.com . Follow us on Facebook ( http://www.facebook.com/NASDAQ ) and Twitter ( http://www.twitter.com/nasdaqomx ). (Symbol: NDAQ and member of S&P 500)

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding NASDAQ-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

-NDAQG -

NASDAQ OMX Media Contact: Christine Barna (646) 441-5310

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Celltrion's ZYMFENTRA Shows Efficacy in Crohn's Disease Study

Updated Category News Views 203

Celltrion's ZYMFENTRA® Demonstrates Efficacy in Crohn's Disease Celltrion, Inc. has recently published promising results from a post-hoc analysis of the LIBERTY-CD study regarding ZYMFENTRA® (infliximab-dyyb). This analysis reveals significant findings about the efficacy of ZYMFENTRA in treating Crohn's disease (CD), regardless of disease location, and it's exciting...

Continue Reading
Akamai Hits Major Milestone with FedRAMP High Ready Status

Updated Category News Views 232

Akamai Cloud Achieves FedRAMP High Ready Status CAMBRIDGE, Mass. – Akamai Technologies, Inc. (NASDAQ: AKAM), a leader in cybersecurity and cloud computing, has proudly announced its recent achievement of the FedRAMP High Ready status. This vital milestone confirms that Akamai is fully prepared to offer federal agencies cloud services that comply with the most rigorous...

Continue Reading
Sam Bankman-Fried's Letter: Claims, Allegations, and Future Hopes

Updated Category News Views 161

Sam Bankman-Fried's Explosive Revelations About FTX In a recently penned letter, former FTX founder Sam Bankman-Fried expressed a firm belief that FTX was never truly insolvent. He attributed much of the downfall of what he called a "$136 billion enterprise" to mismanagement by attorneys, laying blame for the financial struggles on those who were supposed to provide legal...

Continue Reading
Kraus Hamdani Aerospace's K1000ULE Unveils New Heights in UAVs

Updated Category News Views 151

Kraus Hamdani Aerospace's K1000ULE Achieves Remarkable Milestone Kraus Hamdani Aerospace, an innovator in autonomy and AI-driven unmanned systems, has announced the inclusion of its K1000ULE UAS in the U.S. Department of Defense's trusted Blue UAS Cleared List and Select List. This recognition marks a significant achievement in the field of unmanned aerial vehicles,...

Continue Reading
VNA & PACS Market Set to Reach $7.92 Billion by 2030

Updated Category News Views 280

Understanding the Vendor Neutral Archive (VNA) & PACS Market Growth The Vendor Neutral Archive (VNA) and Picture Archiving and Communication System (PACS) market is entering an exciting growth phase. This market, valued at approximately US$4.62 billion recently, is predicted to experience a significant uptick as it is forecasted to expand at a remarkable compound annual...

Continue Reading